S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
Log in
NYSEAMERICAN:SYN

Synthetic Biologics Stock Forecast, Price & News

$0.81
-0.04 (-5.00 %)
(As of 01/27/2021 05:29 PM ET)
Add
Compare
Today's Range
$0.75
Now: $0.81
$0.85
50-Day Range
$0.32
MA: $0.37
$0.50
52-Week Range
$0.25
Now: $0.81
$1.70
Volume10.67 million shs
Average Volume40.68 million shs
Market Capitalization$16.14 million
P/E RatioN/A
Dividend YieldN/A
Beta2.29
Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an early-stage oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.
Synthetic Biologics logo

MarketRank

Overall MarketRank

1.19 out of 5 stars

Medical Sector

834th out of 1,926 stocks

Pharmaceutical Preparations Industry

418th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:SYN
CUSIPN/A
Phone+1-734-3327800
Employees11
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.35) per share

Profitability

Net Income$-15,300,000.00

Miscellaneous

Market Cap$16.14 million
Next Earnings Date2/18/2021 (Estimated)
OptionableNot Optionable
$0.81
-0.04 (-5.00 %)
(As of 01/27/2021 05:29 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions

How has Synthetic Biologics' stock price been impacted by Coronavirus?

Synthetic Biologics' stock was trading at $0.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SYN shares have increased by 124.3% and is now trading at $0.8075.
View which stocks have been most impacted by COVID-19
.

Is Synthetic Biologics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Synthetic Biologics stock.
View analyst ratings for Synthetic Biologics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Synthetic Biologics?

Wall Street analysts have given Synthetic Biologics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Synthetic Biologics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Synthetic Biologics' next earnings date?

Synthetic Biologics is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Synthetic Biologics
.

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) posted its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.14) EPS for the quarter.
View Synthetic Biologics' earnings history
.

When did Synthetic Biologics' stock split? How did Synthetic Biologics' stock split work?

Synthetic Biologics's stock reverse split on the morning of Monday, August 13th 2018. The 1-35 reverse split was announced on Wednesday, August 1st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 10th 2018. An investor that had 100 shares of Synthetic Biologics stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for SYN?

2 brokers have issued twelve-month price targets for Synthetic Biologics' shares. Their forecasts range from $1.25 to $1.50. On average, they expect Synthetic Biologics' share price to reach $1.38 in the next year. This suggests a possible upside of 70.3% from the stock's current price.
View analysts' price targets for Synthetic Biologics
or view Wall Street analyst' top-rated stocks.

Are investors shorting Synthetic Biologics?

Synthetic Biologics saw a drop in short interest in December. As of December 31st, there was short interest totaling 206,900 shares, a drop of 36.0% from the December 15th total of 323,300 shares. Based on an average daily trading volume, of 665,500 shares, the short-interest ratio is presently 0.3 days.
View Synthetic Biologics' Short Interest
.

Who are some of Synthetic Biologics' key competitors?

What other stocks do shareholders of Synthetic Biologics own?

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the following people:
  • Mr. Steven A. Shallcross CPA, CEO, CFO, Treasurer, Corp. Sec. & Director (Age 60, Pay $989.81k)
  • Vincent I. Perrone, Director of Corp. Communication
  • Dr. Vince Wacher, Head of Product and Corp. Devel.
  • Dr. Michael Kaleko, Sr. VP of R&D
  • Ms. Lara M. Guzman, Sr. Director of Project Operations

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $0.81.

How big of a company is Synthetic Biologics?

Synthetic Biologics has a market capitalization of $16.14 million. Synthetic Biologics employs 11 workers across the globe.

What is Synthetic Biologics' official website?

The official website for Synthetic Biologics is www.syntheticbiologics.com.

How can I contact Synthetic Biologics?

Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.